This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bauman, D. R. Articles by Penning, T. M. Search for Related Content PubMed PubMed Citation Articles by Bauman, D. R. Articles by Penning, T. M.

Identification of the Major Oxidative 3-Hydroxysteroid Dehydrogenase in Human Prostate That Converts 5-Androstane-3,17ß-diol to 5-Dihydrotestosterone: A Potential Therapeutic Target for Androgen-Dependent Disease

Department of Pharmacology (D.R.B., S.S., M.V.W., T.M.P), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6084; and Department of Urology (D.M.P.), Stanford University School of Medicine, Stanford, California 94305

Address all correspondence and requests for reprints to: Trevor M. Penning, Department of Pharmacology, University of Pennsylvania School of Medicine, 130C John Morgan Building, 3620 Hamilton Walk, Philadelphia, Pennsylvania 19104-6084. E-mail: penning{at}pharm.med.upenn.edu.

Androgen-dependent prostate diseases initially require 5-dihydrotestosterone (DHT) for growth. The DHT product 5-androstane-3,17ß-diol (3-diol), is inactive at the androgen receptor (AR), but induces prostate growth, suggesting that an oxidative 3-hydroxysteroid dehydrogenase (HSD) exists. Candidate enzymes that posses 3-HSD activity are type 3 3-HSD (AKR1C2), 11-cis retinol dehydrogenase (RODH 5), L-3-hydroxyacyl coenzyme A dehydrogenase , RODH like 3-HSD (RL-HSD), novel type of human microsomal 3-HSD, and retinol dehydrogenase 4 (RODH 4). In mammalian transfection studies all enzymes except AKR1C2 oxidized 3-diol back to DHT where RODH 5, RODH 4, and RL-HSD were the most efficient. AKR1C2 catalyzed the reduction of DHT to 3-diol, suggesting that its role is to eliminate DHT. Steady-state kinetic parameters indicated that RODH 4 and RL-HSD were high-affinity, low-capacity enzymes whereas RODH 5 was a low-affinity, high-capacity enzyme. AR-dependent reporter gene assays showed that RL-HSD, RODH 5, and RODH 4 shifted the dose-response curve for 3-diol a 100-fold, yielding EC₅₀ values of 2.5 x 10^–9 M, 1.5 x 10^–9 M, and 1.0 x 10^–9 M, respectively, when compared with the empty vector (EC₅₀ = 1.9 x 10^–7 M). Real-time RT-PCR indicated that L-3-hydroxyacyl coenzyme A dehydrogenase and RL-HSD were expressed more than 15-fold higher compared with the other candidate oxidative enzymes in human prostate and that RL-HSD and AR were colocalized in primary prostate stromal cells. The data show that the major oxidative 3-HSD in normal human prostate is RL-HSD and may be a new therapeutic target for treating prostate diseases.

NURSA Molecule Pages Link:

Nuclear Receptors:   AR

Ligands:   Dihydrotestosterone

This article has been cited by other articles:

				Y. Jin, L. Duan, S. H. Lee, H. J. Kloosterboer, I. A. Blair, and T. M. Penning Human Cytosolic Hydroxysteroid Dehydrogenases of the Aldo-ketoreductase Superfamily Catalyze Reduction of Conjugated Steroids: IMPLICATIONS FOR PHASE I AND PHASE II STEROID HORMONE METABOLISM J. Biol. Chem., April 10, 2009; 284(15): 10013 - 10022. [Abstract] [Full Text] [PDF]

				J. M Day, H. J Tutill, A. Purohit, and M. J Reed Design and validation of specific inhibitors of 17{beta}-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr. Relat. Cancer, September 1, 2008; 15(3): 665 - 692. [Abstract] [Full Text] [PDF]

				W. C. Cooper, Y. Jin, and T. M. Penning Elucidation of a Complete Kinetic Mechanism for a Mammalian Hydroxysteroid Dehydrogenase (HSD) and Identification of All Enzyme Forms on the Reaction Coordinate: THE EXAMPLE OF RAT LIVER 3{alpha}-HSD (AKR1C9) J. Biol. Chem., November 16, 2007; 282(46): 33484 - 33493. [Abstract] [Full Text] [PDF]

				C. Wang, P. Christenson, and R. Swerdloff Clinical Relevance of Racial and Ethnic Differences in Sex Steroids J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2433 - 2435. [Full Text] [PDF]

				S. Rohrmann, W. G. Nelson, N. Rifai, T. R. Brown, A. Dobs, N. Kanarek, J. D. Yager, and E. A. Platz Serum Estrogen, But Not Testosterone, Levels Differ between Black and White Men in a Nationally Representative Sample of Americans J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2519 - 2525. [Abstract] [Full Text] [PDF]

				O. V. Belyaeva, S. V. Chetyrkin, A. L. Clark, N. V. Kostereva, K. S. SantaCruz, B. M. Chronwall, and N. Y. Kedishvili Role of Microsomal Retinol/Sterol Dehydrogenase-Like Short-Chain Dehydrogenases/Reductases in the Oxidation and Epimerization of 3{alpha}-Hydroxysteroids in Human Tissues Endocrinology, May 1, 2007; 148(5): 2148 - 2156. [Abstract] [Full Text] [PDF]

				D. R. Bauman, S. Steckelbroeck, D. M. Peehl, and T. M. Penning Transcript Profiling of the Androgen Signal in Normal Prostate, Benign Prostatic Hyperplasia, and Prostate Cancer Endocrinology, December 1, 2006; 147(12): 5806 - 5816. [Abstract] [Full Text] [PDF]